Genova Biotherapeutics (1461 A. First Ave #360, New York, NY 10021-2209, phone +1 646-845-1920) a bioscience company developing novel therapeutic proteins that are designed to disrupt the advance of life-threatening cancers, today, released important information about its innovative method for destroying breast cancer cells, using stem cell technology.The approach is based on cutting-edge technology that enables researchers and physicians to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures. “By recognizing the existence of cancer stem cells, we have taken a great step towards understanding this complex disease. Now that we know how to identify the unique characteristics of these stem cells, we can develop cell-specific therapies that can eradicate them, and thus neutralize breast cancer right at the source,” explains John Savin, VP for GENovaThe key behind GENova’s biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose. Now that they are identifiable, scientists are developing tailor-made proteins that are programmed to destroy cancerous cells, whilst leaving the healthy cells intact. GENova has targeted these bio-engineered proteins for acquisition into its growing anti-cancer drug pipeline.In the future, this technology will also enable us to identify healthy stem cells and then develop, inject, and nurture them in such a way that they can overcome the malignant cells. Eventually, healthy stem cells will overcome the sick cells, leaving the patient cured. This novel method for treating breast cancer is far superior to existing treatments, and is the underpinning of GENova’s IP (Intellectual Property) portfolio.Development of this important biotechnology would mean a new cure for cancer, rendering disfiguring mastectomies and harmful radiation therapies obsolete.

Advertisement #5